Xtant Medical Holdings, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 16, 2026, disclosing operational details, strategic developments, and a share count of 140,452,061 as of November 13, 2026.

Key Highlights

  • Share count: 140,452,061 shares of common stock were outstanding as of November 13, 2026, according to the filing.
  • Exchange listing: Common stock, par value $0.000001 per share, trades under the symbol XTNT on NYSE American LLC.
  • Strategic review: The company disclosed that its Board of Directors is conducting a review of "a broad range of strategic, operational and financial alternatives."
  • HEMOBLAST distribution: Xtant Medical distributes the HEMOBLAST Bellows product on an exclusive basis under an agreement with Dilon Technologies, Inc., and hired approximately 20 additional sales personnel in connection with that arrangement.
  • Exclusivity fee: Dilon holds the right to terminate the distribution agreement subject to repayment of a $5.0 million exclusivity fee, and may exercise that right at any time, according to the filing.
  • Asset sale: The filing references the sale of certain assets relating to the Coflex and CoFix products and the international hardware business to Companion Spine, LLC.
  • Company classification: Xtant Medical is classified as a non-accelerated filer and a smaller reporting company under SEC definitions, the filing states.

Xtant Medical's Q3 2026 Quarterly Disclosure and Strategic Developments

Xtant Medical Holdings, Inc., headquartered at 664 Cruiser Lane, Belgrade, Montana 59714, filed its quarterly report on Form 10-Q with the SEC for the period ending September 30, 2026. The company, which trades on NYSE American LLC under the ticker XTNT, describes itself as operating through wholly owned subsidiaries whose results are consolidated in its condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation, according to the filing.

A prominent disclosure in the quarterly report concerns the Board of Directors' ongoing review of "a broad range of strategic, operational and financial alternatives." The filing identifies a range of risks associated with that review, including potential effects on employees, independent agents, customers, and suppliers, as well as uncertainty regarding "the scope, timing, conduct and potential outcomes of the review." The company also states its objective to "improve execution, improve financial performance, and maximize stockholder value," characterizations the filing attributes to the company's own forward-looking statements, which are subject to its cautionary language.

The filing describes Xtant Medical's exclusive distribution agreement with Dilon Technologies, Inc. for the HEMOBLAST Bellows product, noting that approximately 20 additional sales personnel were hired in connection with the arrangement. The company identifies a material risk in that Dilon retains the right to terminate the agreement at any time upon repayment of a $5.0 million exclusivity fee, which the filing says "would cause us to lose our rights to sell the HEMOBLAST Bellows product in the United States." Additionally, the filing references the prior sale of assets related to the Coflex, CoFix, and international hardware business to Companion Spine, LLC. The company also states its intention to become "a larger and more diverse producer of biologics" by controlling its supply chain and reducing reliance on outside manufacturing.

What Was Disclosed

Xtant Medical Holdings, Inc. submitted a Form 10-Q for the quarter ended September 30, 2026, covering share count, exchange listing, a Board-level strategic alternatives review, the HEMOBLAST Bellows distribution agreement with Dilon Technologies, and an asset sale to Companion Spine, LLC.